EDIT Overview

Editas Medicine, Inc. is a genome-editing company developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms and foundational intellectual property for both CRISPR systems. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide RNA molecule designed to recognize a particular DNA sequence. It is engaged in discovering, developing, manufacturing, and commercializing durable, precision in vivo gene-editing medicines for a broad class of diseases. Vivo medicines include vivo editing of hematopoietic stem cells (HSCs), liver cells and other tissues. Vivo gene editing in HSCs supports the advancement of research programs to treat non-malignant hematological diseases.

Wall Street analysts forecast EDIT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EDIT is3.78 USD with a low forecast of 3.00 USD and a high forecast of 4.60 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Editas Medicine Inc revenue for the last quarter amounts to 2.83M USD, decreased -39.22

Editas Medicine Inc. EPS for the last quarter amounts to -0.26 USD, decreased -71.74

Editas Medicine Inc (EDIT) has 87 emplpoyees as of May 11 2026.

Today EDIT has the market capitalization of 304.49M USD.